We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+40.24%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$356M
AUM Growth
+$164M
Cap. Flow
+$115M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.6%
Holding
52
New
19
Increased
13
Reduced
10
Closed
8

Top Buys

1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$20.1M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.7M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$7.91M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$7.48M
5
ALT icon
Altimmune
ALT
+$6.42M

Top Sells

1
SGEN
Seagen Inc. Common Stock
SGEN
+$5.7M
2
MRUS
Merus
MRUS
+$5.66M
3
FOLD
Amicus Therapeutics
FOLD
+$5.57M
4
ARVN icon
Arvinas
ARVN
+$4.63M
5
COGT icon
Cogent Biosciences
COGT
+$4.11M

Sector Composition

1 Healthcare 68.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$39.7M 11.13%
500,000
+100,000
+25% +$8.43M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$18.8M 5.27%
275,000
+50,000
+22% +$2.96M
RLMD icon
3
PUT
Relmada Therapeutics
RLMD
$550M
$18.5M 5.2%
+500,000
New +$13.9M
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$18.2M 5.11%
+725,000
New +$20.1M
RLMD icon
5
Relmada Therapeutics
RLMD
$550M
$15.7M 4.42%
425,000
+175,000
+70% +$4.85M
AMLX icon
6
Amylyx Pharmaceuticals
AMLX
$1.97B
$15.5M 4.35%
+550,000
New +$13.7M
DICE
7
CALL
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.2M 3.98%
700,000
+550,000
+367% +$10M
AMLX icon
8
PUT
Amylyx Pharmaceuticals
AMLX
$1.97B
$14.1M 3.95%
+500,000
New +$12.5M
AXSM icon
9
Axsome Therapeutics
AXSM
$11.8B
$13.4M 3.76%
300,000
+75,000
+33% +$3.75M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.2M 3.43%
175,000
+65,000
+59% +$4.81M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.82B
$12.2M 3.41%
110,000
-20,000
-15% -$2.02M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$11.6M 3.27%
2,000,000
+1,200,000
+150% +$7.48M
VRDN icon
13
Viridian Therapeutics
VRDN
$1.99B
$11M 3.08%
535,000
-65,000
-11% -$1.17M
RVNC
14
DELISTED
Revance Therapeutics, Inc.
RVNC
$10.5M 2.96%
+390,000
New +$7.91M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.1B
$9.81M 2.75%
95,000
+20,000
+27% +$1.9M
COGT icon
16
Cogent Biosciences
COGT
$6.68B
$8.95M 2.51%
600,000
-300,000
-33% -$4.11M
PCVX icon
17
Vaxcyte
PCVX
$8.12B
$8.64M 2.43%
360,000
+35,000
+11% +$887K
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.32M 2.34%
463,700
-36,300
-7% -$476K
SGEN
19
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$6.84M 1.92%
+50,000
New +$8.15M
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.75M 1.89%
30,000
-15,000
-33% -$3.04M
AXSM icon
21
CALL
Axsome Therapeutics
AXSM
$11.8B
$6.69M 1.88%
+150,000
New +$7.5M
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.36B
$6.62M 1.86%
525,000
+200,000
+62% +$2.57M
ALT icon
23
Altimmune
ALT
$558M
$5.55M 1.56%
+435,000
New +$6.42M
TCDA
24
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$5.24M 1.47%
+500,000
New +$5.47M
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$5.22M 1.47%
500,000
-500,000
-50% -$5.57M
1
2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ghost Tree Capital held 52 positions worth $356M, up 86% from $192M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ghost Tree Capital deployed $115M of net new capital in Q3 2022, opening 19 new positions and adding to 13 existing holdings. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 725,000 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 76% a quarter earlier.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $5.57M trimmed.

  • Ghost Tree Capital's largest Q3 2022 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 725,000 shares worth $18.2M.
  • Ghost Tree Capital added most to CTI BioPharma Corp. (DE) Common Stock in Q3 2022, an estimated $7.48M increase.
  • Ghost Tree Capital's biggest Q3 2022 reduction was Amicus Therapeutics, cutting an estimated $5.57M.
  • Ghost Tree Capital fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $5.7M.
  • Ghost Tree Capital's ten largest holdings make up 51% of its $356M portfolio in Q3 2022.
  • Ghost Tree Capital opened 19 new positions and closed 8 in Q3 2022.
  • Ghost Tree Capital's portfolio value rose 86% quarter-over-quarter to $356M.

Based on Ghost Tree Capital's 13F filing for Q3 2022, filed 14 Nov 2022.